Panasonic and Institute of Microchemical Technology Co., Ltd. Jointly Develop Mass Production Technology for Microfluidic Devices by Glass Molding, a First in the Industry*1
6.11.2019 05:17:00 EET | Business Wire | Press release
Panasonic Corporation (Panasonic) and Institute of Microchemical Technology Co., Ltd. (IMT) jointly developed a technology for mass production of microfluidic devices*2 using a glass molding. Compared to the conventional glass etching method, this technology realizes low cost (about 1/10) and highly accurate (about 10 times) mass production. These devices can be applied to sensing and analysis for medical, biological, environmental (water and air quality) applications, etc. The companies will start accepting prototype orders from FY2019, and are planning to start mass production from FY2020. Panasonic and IMT will present and exhibit this device at the 40th meeting of Society for Chemistry and Micro-Nano Systems (CHEMINAS 40th) held at Act City Hamamatsu in Hamamatsu City, Shizuoka Prefecture, Japan from November 19th to 21st.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191105006302/en/
Microfluidic device technology (Graphic: Business Wire)
[Effect]
Conventional glass microfluidic devices have not been widely used, because of high cost and poor precision. This development achieved mass production and cost reduction of glass microfluidic devices by combining IMT's microfluidic device design technology and Panasonic's glass molding technology. As a result, disposable use of glass microfluidic devices becomes possible. In addition, by realizing high precision, it is easy to incorporate the device as a part of equipment and systems.
[Application]
By taking advantage of the environmental and chemical resistance of glass microfluidic devices, it can be applied to environmental sensing, blood testing, and pharmaceutical equipment as disposable detection devices for analysis and testing in outdoor and harsh environments.
[Characteristic]
The newly developed microfluidic device has the following features.
1. Up to φ50mm size
2. More than 10,000 devices per month of production capacity
3. Manufacturing process with the shape precision of about 1μm
[Technology]
This development is realized by the following technologies.
(1) Design and interface technology of microfluidic device optimized for glass molding
(2) Microstructure mold processing technology to higher hardness material and microstructural glass molding technology to precisely transfer to glass
(3) Thermal bonding technology to join a flat glass plate and a plate with microstructures.
Notes:
*1: As of November 6, 2019, Panasonic survey
*2: A device that can perform various chemical processes (mixing, reaction, extraction, synthesis, detection) in a minute flow path with a small amount and high efficiency by flowing liquid through a groove with a width and depth of several hundreds of micrometers.
[Background]
General microfluidic device made of glass used in microfluidics technology [1] is mainly produced by etching techniques. After drawing the flow path pattern by photolithography, the glass flow path is formed by etching, and the cover glass with the machined introduction hole is bonded. Since the inception of this field, IMT has provided high-level products as a pioneer in the planning, design and manufacture of glass microfluidic devices. However, in addition to the skill required for manual manufacturing, the manufacturing process took several months. For this reason, the manufacturing time and cost per piece became a hurdle, and generalization and industrial mounting were not realized, and the use was limited mainly to basic research applications.
On the other hand, Panasonic has been developing and manufacturing glass molding technology [2] from the 1980s, that has contributed to the commercialization of the world's highest level of optical device. They are used in lenses for various optical devices, like digital still cameras.
By combining Panasonic's glass molding technology and IMT design technology, it became possible to develop microstructure mold machining technology, molding technology, and joining technology suitable for mass production of microfluidic devices using glass molding technology. The companies have succeeded in developing mass production technology for microfluidic devices. As a result, it is possible to reduce the cost to about 1/10 compared to the conventional manufacturing method, and to supply glass microfluidic devices with improved precision 10 times or more in less than half the delivery time.
[Practical realization]
With the development of mass production technology for microfluidic devices [3] using this glass molding technology, glass microfluidic devices are widely used as disposable detection devices for analysis and testing in outdoor and harsh environments, and for disposable devices for blood testing equipment.
[Explanation of terms]
[1] Microfluidic device technology
This technology integrates chemical processes such as mixing, reaction, separation, extraction, synthesis, and detection in a flow channel of several tens to several hundreds of μm created on a substrate (microfluidic device) of several cm square. By freely integrating chemical processes that have been performed in laboratories and factories in the microspace of microfluidic devices, it becomes possible to use energy and space much more efficiently. It is expected to contribute greatly to the evolution of chemical technology in the future. This chemical process integration technology (microfluidic technology) in the micro space was established as a result of research and development of the Kitamori “Integrated Chemistry” project. The project was carried out at Kitamori Lab., Department of Applied Chemistry, School of Engineering, The University of Tokyo, and Kanagawa Academy of Science and Technology (currently Kanagawa Institute of Industrial Science and Technology).
[2] Glass molding technology (mold machining technology, mold protection coating technology, molding technology)
[3] Application examples of microfluidic devices using glass molding technology
About Panasonic
Panasonic Corporation is a worldwide leader in the development of diverse electronics technologies and solutions for customers in the consumer electronics, housing, automotive, and B2B businesses. The company, which celebrated its 100th anniversary in 2018, has expanded globally and now operates 582 subsidiaries and 87 associated companies worldwide, recording consolidated net sales of 8.003 trillion yen for the year ended March 31, 2019. Committed to pursuing new value through innovation across divisional lines, the company uses its technologies to create a better life and a better world for its customers. To learn more about Panasonic: https://www.panasonic.com/global.
About Institute of Microchemical Technology
IMT is a pioneer company of microchemical chip technology (microfluidics) and was founded in 2001 as a venture company of the University of Tokyo and Kanagawa Institute of Industrial Science and Technology (formerly Kanagawa Academy of Science and Technology).
IMT manufactures and sells microchemical chips, their peripheral equipment and system devices.
Company Name: Institute of Microchemical Technology Co., Ltd (IMT)
Capital: 100M JPY
Foundation: May 1st, 2001
Address: A-19 AIRBIC, 7-7 Shinkawasaki, Saiwai, Kawasaki, Kanagawa 212-0032 Japan
TEL: +81-44-201-9889 FAX: +81-44-201-9890
HP: https://www.i-mt.co.jp/en/
Source: https://news.panasonic.com/global/press/data/2019/11/en191106-3/en191106-3.html
Related Links
Industrial Devices & Solutions - Panasonic
https://industrial.panasonic.com/ww
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191105006302/en/
Contact information
Panasonic
Innovation Strategy Office
Technology Public Relations Section
crdpress@ml.jp.panasonic.com
[Inquiries for prototypes]
Institute of Microchemical Technology Co., Ltd.
Email:info@i-mt.co.jp Tel: +81-44-201-9889
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 14:00:00 EEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 13:41:00 EEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 11:00:00 EEST | Press release
A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal opportunities across the Group’s production sites and communities. These are just some of the “sustainability” stories the Barilla Group is sharing on World Environment Day with the publication of its 2025 Sustainability Report. The report comes just after Barilla was named the world’s most reputable company in the food sector for the third year running and, for the first time, ranked among the global top 10 in the Global RepTrak 100 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603162436/en/ “The future of the planet will increasingly depend on our ability to spread culture and education,” says Paolo Barilla, Vic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
